If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-09. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
== Genetics == The biologic instructions for synthesising protein C in humans are encoded in the gene officially named "protein C (inactivator of coagulation factors Va and VIIIa)". The gene's symbol approved by the HUGO Gene Nomenclature Committee is "PROC" from "protein C". It is located on the second chromosome (2q13-q14) and comprises nine exons. The nucleotide sequence that codes for human protein C is approximately 11,000 bases long.
== In fungi == There are a variety of saprophytic and parasitic organisms that have evolved the habit of growing into their substrates as thin strands for extracellular digestion. This is most typical of the "true" fungi, but it has also evolved in Actinomycetota (Bacteria), oomycetes (which are part of the stramenopile grouping, as are kelp), parasitic plants, and rhizocephalans (parasitic barnacles). Slime molds are traditionally classified as fungi, but molecular-phylogeny work has revealed that most slime molds are not very close to Fungi proper and similar organisms, and that their slime-mold habit has originated several times. Mycetozoa (Amoebozoa), Labyrinthulomycetes (Stramenopiles), Phytomyxea and Guttulinopsis vulgaris (Rhizaria), Acrasidae (Heterolobosea), Fonticula alba (Opisthokonta), and Myxobacteria (Bacteria). Mycetozoa itself contains myxogastrids, dictyostelids, and protostelids, likely with separate origins, with protostelids themselves likely originating several times. Specialized forms of osmotrophy are found in unrelated fungi and animals.
=== Newborn screening === Several countries test all newborns for SCID as a part of routine newborn screening. A measure using real-time quantitative PCR of the blood concentration of T-cell receptor excision circles (TRECs), which are reduced in SCID, is the method used to screen all U.S. newborns for SCID. As of September 2022, the known percentage of newborns screened has increased throughout the world with 100% in the United States, 100% in Australia, 78% in Europe, 32% in Latin America, 26% in the Middle East and North Africa, 13% in Asia-Pacific, and 0% in Central America. The introduction of newborn screenings and genetic testing in many countries has allowed early detection and treatment before the development of severe infections, which progressively improved the five-year survival rate for newborns with SCID to around 90%.
Xenobiotic metabolism (from the Greek xenos "stranger" and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as drugs and poisons. These pathways are a form of biotransformation present in all major groups of organisms, and are considered to be of ancient origin. These reactions often act to detoxify poisonous compounds; however, in cases such as in the metabolism of alcohol, the intermediates in xenobiotic metabolism can themselves be the cause of toxic effects. Xenobiotic metabolism is divided into three phases. In phase I, enzymes such as cytochrome P450 oxidases introduce reactive or polar groups into xenobiotics. These modified compounds are then conjugated to polar compounds in phase II reactions. These reactions are catalysed by transferase enzymes such as glutathione S-transferases. Finally, in phase III, the conjugated xenobiotics may be further processed, before being recognised by efflux transporters and pumped out of cells. The reactions in these pathways are of particular interest in medicine as part of drug metabolism and as a factor contributing to multidrug resistance in infectious diseases and cancer chemotherapy. The actions of some drugs as substrates or inhibitors of enzymes involved in xenobiotic metabolism are a common reason for hazardous drug interactions.
Sources: en.wikipedia.org
=== Singles series and Full Cold Moon (2012–present) === In September 2012, Eisold announced Cold Cave would be touring the US later in the year, he would be recording a new album, and that the new live lineup included: Hunter Burgan (AFI), London May (Samhain), Jessie Nelson, and Cody Votolato (The Blood Brothers). This lineup was exclusive to this two-and-a-half-week tour and Eisold said performing with a full band was something that failed to materialize during Cherish the Light Years tours. While continuing to work on a follow-up to Cherish the Light Years and not under contract with a label, Eisold began independently releasing a series of stand-alone singles. Eisold wrote and recorded these new songs by himself similar to how songs on Cremations and Love Comes Close were crafted. He said they were created "by myself, at a desk in my apartment. It was freeing and exciting in a way because I didn't owe anyone an album. I got to just make them to make them. The songs were minimal, honest, electronic and without help." The first single in the series was "A Little Death to Laugh." The single was released in October 2012 through Heartworm and a music video for the song was released in March 2013. In 2013, Eisold released "Oceans with No End" (through Jacob Bannon's Deathwish Inc.), "God Made the World" and "Black Boots", for which Slava Tsukerman, known for his 1982 film Liquid Sky, directed a music video. In October 2013, Cold Cave released a digital-only, fifth stand-alone single titled "Nausea, The Earth and Me."
== History == The Blood Products Laboratory was established in 1954 as part of the Lister Institute of Preventive Medicine and initially run by the Medical Research Council until its transfer to the National Health Service (NHS) in 1978. BPL's predecessor organisation was established in 1943. Lister purchased the Elstree site in 1902 and operated on the site until 1978. During this time, Professor R. A.Kekwick, working at the Lister Institute undertook experimental and production work with A.S. McFarlane. The two scientists devised a process to clarify outdated blood plasma to render it suitable for transfusion. Laboratory testing was undertaken in the historic Queensbury Lodge, the site of Joseph Lister's laboratory. In 1943, Kekwick was appointed Head of the Lister's Biophysics Division, Kekiwick established the Blood Filtration Unit and he and his team worked on methods of freeze-drying plasma and then of separating out proteins in blood plasma. These early products were used to meet the needs of the Armed Services and civilian establishments. In 1948 the Blood Filtration Unit came under the joint management of the Medical Research Council (MRC) and the Lister Institute, and the name was changed to the Blood Products Research Unit and it occupied the newly built laboratories (or 'Building 25'). The aim of the Unit was directed towards the preparation of plasma fractions for clinical use During the 1940s, Brinkhous and McFarlane discovered that transfusions using whole blood or plasma provided a means of FVIII replacement.
=== Medical conditions === There are a number of medications and other health problems that can predispose to diabetes. Some of the medications include: glucocorticoids, thiazides, beta blockers, atypical antipsychotics, and statins. Those who have previously had gestational diabetes are at a higher risk of developing type 2 diabetes. Other health problems that are associated include: acromegaly, Cushing's syndrome, hyperthyroidism, pheochromocytoma, and certain cancers such as glucagonomas. Individuals with cancer may be at a higher risk of mortality if they also have diabetes. Testosterone deficiency is also associated with type 2 diabetes. Eating disorders may also interact with type 2 diabetes, with bulimia nervosa increasing the risk and anorexia nervosa decreasing it.
Testosterone is the primary male sex hormone and androgen in males. In humans, testosterone drives the development of male reproductive tissues such as testicles and prostate, as well as promoting secondary sexual characteristics such as increased muscle and bone mass, and the growth of body hair. It is associated with increased aggression, sex drive, dominance, courtship display, and a wide range of behavioral characteristics. In addition, testosterone in both sexes is involved in health and well-being, where it has a significant effect on overall mood, cognition, social and sexual behavior, metabolism and energy output, the cardiovascular system, and in the prevention of osteoporosis. Insufficient levels of testosterone in men may lead to abnormalities including frailty, accumulation of adipose fat tissue within the body, anxiety and depression, sexual performance deficits, and bone loss. Excessive levels of testosterone in men may be associated with hyperandrogenism, higher risk of heart failure, increased mortality in men with prostate cancer, and male pattern baldness. Testosterone is a steroid hormone from the androstane class containing a ketone and a hydroxyl group at positions three and seventeen respectively. It is biosynthesized in several steps from cholesterol and is converted in the liver to inactive metabolites. It exerts its action through binding to and activation of the androgen receptor. In humans and most other vertebrates, testosterone is secreted primarily by the testicles of males and, to a lesser extent, the ovaries of females.
Trump formally notified the United States Congress on 1 October 2025 that the US was in a "non-international armed conflict" with "unlawful combatants" regarding drug cartels in the Caribbean, specifically referencing the 15 September strike. The Miami Herald wrote that: "In an armed conflict, a country can lawfully kill enemy fighters even when they pose no threat." Initially positioned as a mission to stop narcotics traffic to the US, by mid-October, Venezuelan opposition figures and independent analysts stated the American objective had shifted to regime change, with Trump acknowledging the possibility of strikes within Venezuelan territory. On 16 October, Admiral Alvin Holsey, the commander of United States Southern Command, announced that he would retire at the end of the year, less than a year into what is normally a three-year placement, with anonymous sources reporting tension between Holsey and the Trump administration over Venezuela. Two unnamed officials told The Wall Street Journal that tension between Hegseth and Holsey began early during Trump's administration over military planning involving the Panama Canal, with Hegseth wanting to replace Holsey, but differences intensified when "Holsey was initially concerned about murky legal authority for the boat strike campaign" and "objected that parts of the operations fell outside his direct control". The sources stated that, after months of tension, there was a confrontational meeting in October, and Holsey's resignation was announced the same day.
Sources: en.wikipedia.org
Homoserine (also called isothreonine) is an α-amino acid with the chemical formula HO2CCH(NH2)CH2CH2OH. L-Homoserine is not one of the common amino acids encoded by DNA. It differs from the proteinogenic amino acid serine by insertion of an additional −CH2− unit into the sidechain. Homoserine, or its lactone, is the product of a cyanogen bromide cleavage of a peptide by degradation of methionine. Homoserine is an intermediate in the biosynthesis of three essential amino acids: methionine, threonine (an isomer of homoserine), and isoleucine.
== Interactions == Phenibut may mutually potentiate and extend the duration of the effects of other CNS depressants, including anxiolytics, antipsychotics, sedatives, opioids, anticonvulsants, and alcohol.
=== Shingrix === Temporary side effects from the Shingrix shots are likely and can be severe enough in one out of six people to affect normal daily activities for up to three days. Mild to moderate pain at the injection site is common, and some may have redness or swelling. Side effects include fatigue, muscle pain, headache, shivering, fever, and nausea. Symptoms usually resolve in two to three days. Side effects with Shingrix are greater than those with Zostavax and occur more frequently in individuals aged 50 to 69 years compared with those 70 years and older.
== History == Justus von Liebig showed in 1829 that hippuric acid differed from benzoic acid and he named it, and in 1834 he determined its constitution, while in 1853 French chemist Victor Dessaignes (1800–1885) synthesized it by the action of benzoyl chloride on the zinc salt of glycine. It was also formed by heating benzoic anhydride with glycine, and by heating benzamide with monochloroacetic acid.
which means that the divergence of the velocity field is zero everywhere. Physically, this is equivalent to saying that the local volume dilation rate is zero, hence a flow of water through a converging pipe will adjust solely by increasing its velocity as water is largely incompressible.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.